🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Akk Gut Bacteria Supplement

    The First People's Hospital of Lianyungang

    Premature Ovarian Failure (POF)

    phase 1 other active

    1 trial

  2. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  3. Allogeneic CD19/BCMA-targeted CAR-γδT cell injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory/Relapsed Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  4. Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  5. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code

    Lacuna Pharma Pty Ltd

    chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia

    phase 1 other active

    1 trial

  6. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  7. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  8. Anti-CD19 Universal CAR-T Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  9. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  10. Anti-CD20 monoclonal antibody and the BTK inhibitor

    The First People's Hospital of Lianyungang

    Anti-CD20 Monoclonal Antibody

    phase 1 small molecule active

    1 trial

  11. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  12. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  13. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  14. Autologous Natural Killer Cell Therapy

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  15. Autologous differentiated myocyte transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metabolic Disease

    phase 1 mab active

    1 trial

  16. Autologous tumor-infiltrating lymphocyte cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 mab terminated

    1 trial

  17. Autologous γδT cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  18. BAO-G

    The First People's Hospital of Lianyungang

    Thoracoabdominal Aortic Aneurysm

    phase 1 other active

    1 trial

  19. BC006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumors (Including GCTTS)

    phase 1 small molecule active

    1 trial

  20. BCMA/CD19 Dual-Target CAR-T

    Xijing Hospital

    Multiple Myeloma

    phase 1 mab active

    1 trial

  21. BZ019

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  22. Biological: LV009 injection

    The First People's Hospital of Lianyungang

    CD19+ Relapse/Refractory B-ALL

    phase 1 small molecule active

    1 trial

  23. Biological: PD-1

    Hospital Authority, Hong Kong

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  24. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources